Date:5/5/2011

ease contains forward–looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales for the Hepatic CHEMOSAT delivery system in the EEA, if any, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales in the United States, if any, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward–looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward–looking statements to reflect events or circumstances after the date they are madeContact Informat
'/>"/>

SOURCE Delcath Systems, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Delcath Names Harold C. Mapes as Executive Vice President of Global Operations
2. Delcath Receives Notice of European Regulatory Approval for Hepatic CHEMOSAT™ Delivery System
3. Delcath to Update Investors on FDA Meeting
4. Delcath Expands Board of Directors With Appointment of Gabriel Leung
5. Delcath to Present at Upcoming Investor Conferences
6. Delcath Systems Receives Refusal to File Letter From FDA
7. Delcath Achieves ISO 13485 Certification
8. Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
9. Delcath Systems Announces Third Quarter Progress Report Conference Call
10. Delcath Strengthens Research and Development Team with Key Appointments
11. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply